Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
OINTMENT
**Dosage and administration** **Adults:** Daivonex® ointment should be applied to the affected area twice daily. For some patients adequate maintenance therapy may be achieved with less frequent application. The maximum amount used by an adult in one week should not exceed 100 g (equivalent to 5 mg of calcipotriol). If using other calcipotriol containing medicinal products concomitantly, the total weekly dose of all calcipotriol containing medical products, including Daivonex® ointment, should not exceed 5 mg of calcipotriol.
TOPICAL
Medical Information
**Indications** Psoriasis vulgaris.
**Contraindications** Hypersensitivity to the active substance or to any of the excipients. Due to the content of calcipotriol, Daivonex® ointment is contraindicated in patients with known disorders of calcium metabolism (see Special warnings and precautions for use – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
D05AX02
calcipotriol
Manufacturer Information
DKSH SINGAPORE PTE. LTD.
LEO LABORATORIES LIMITED
Active Ingredients
Documents
Package Inserts
Daivonex ointment PI.pdf
Approved: August 26, 2019